基于VI-RADS的膀胱癌管理算法:随机回顾性研究
本研究评估VI-RADS能否区分非肌层浸润性膀胱癌(NMIBC)、肌层浸润性膀胱癌(MIBC)及高危NMIBC(HR-NMIBC),并探讨基于VI-RADS的新算法能否替代重复经尿道膀胱肿瘤电切术(Re-TURBT)。283例中VI-RADS≥3判断肌层浸润的敏感度95.7%、特异度92.5%,AUC 0.942(P<.001)。作者认为新算法有助于VI-RADS≥4患者转向根治性治疗,但VI-RADS≤2者残留病变比例高,即使排除不完全切除,仍应继续TURBT。
要点
- VI-RADS≥3判断肌层浸润的敏感度95.7%、特异度92.5%,AUC 0.942(P<.001)。
- 按新算法,178例VI-RADS≤2的HR-NMIBC中73例(41%)将不做Re-TURBT。
- 75例VI-RADS≥4患者中6例(8%)HR-NMIBC将不做Re-TURBT。
核心结论
- 基于VI-RADS的新算法通过使VI-RADS≥4患者转向根治性治疗而对其有帮助。
- 由于VI-RADS≤2病例中残留病变比例高,即使排除不完全切除,作者认为仍应继续TURBT。
研究设计与样本
- 随机回顾性研究,共纳入283例接受TURBT的患者,其中89例接受Re-TURBT。
- 计算VI-RADS评分在mpMRI中的敏感度、特异度、阳性预测值(PPV)和阴性预测值(NPV)。
主要发现
- 283例中,以VI-RADS≥3病变视为肌层浸润时,敏感度95.7%、特异度92.5%,PPV 86.6%、NPV 97.7%,AUC 0.942(P<.001)。
- 89例接受Re-TURBT的患者中,41例(46%)无肿瘤,47例(50.5%)为持续性HR-NMIBC,3例(2.2%)升级为MIBC。
- 按新的VI-RADS算法,178例VI-RADS≤2的HR-NMIBC中73例(41%)将不做Re-TURBT。
- 75例VI-RADS≥4患者中,6例(8%)HR-NMIBC将不做Re-TURBT。
- 排除不完全切除后,35例(60.3%)为完全切除,23例(39.7%)有残留病变,且这些患者未行完全切除,其中2例(100%)仍有残留病变。
临床怎么用
- 作者认为新算法可使VI-RADS≥4患者转向根治性治疗。
- 作者认为VI-RADS≤2病例残留病变比例高,即使排除不完全切除,仍应继续TURBT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate if VI-RADS can distinguish between nonmuscle-invasive bladder cancers (NMIBC), muscle-invasive bladder cancer (MIBC), and high-risk nonmuscle-invasive bladder cancers (HR-NMIBCs). It is unclear if the Vesical Imaging-Reporting and Data System (VI-RADS) can replace repeated transurethral resection of bladder tumor (Re-TURBT) as in the new VI-RADS-based algorithm. METHODS: Sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values of the VI-RADS score were calculated for mpMRI performance in patients undergoing TURBT and HR-NMIBC patients for only Re-TURBT. RESULTS: Of 283 cases, when VI-RADS ≥3 lesions were considered muscle-invasive, its sensitivity was 95.7% and specificity was 92.5%. PPV and NPV were 86.6% and 97.7%, respectively. The area under the curve (AUC) was 0.942 (P <.001). Of 89 patients undergoing post-Re-TURBT, 41 (46%) were tumor-free, 47 (50.5%) showed permanent HR-NMIBC, and 3 (2.2%) were upgraded to MIBC. Per the new VI-RADS-based approach, 73 (41%) of the 178 HR-NMIBCs with VI-RADS ≤2 would not undergo Re-TURBT. Of the 75 patients with VI-RADS ≥4, 6 (6) with HR-NMIBCs (8%) would not undergo Re-TURBT. When incomplete resections were excluded, 35 (60.3%) of the patients had complete resection, 23 (39.7%) had residual disease, and complete resection would not have been performed in these patients, and 2 (100%) still had residual disease. CONCLUSION: The new VI-RADS-based algorithm helped VI-RADS ≥4 patients by switching to radical treatment. Since the residual disease is high in cases with VI-RADS ≤2, even if incomplete resections are excluded, TURBT should be continued.
引用
- Şam Özdemir M, Keskin ET, Savun M, et al. VI-RADS-based Algorithm for Bladder Cancer Management Randomized Retrospective Study. Urology. 2024. PMID: 39426738. doi:10.1016/j.urology.2024.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。